Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced triple-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor tests positive for PD-L1 (a protein that helps the cancer hide from your immune system) with a CPS score of 1 or higher.
- You have already finished 6 cycles of standard first-line immunotherapy combined with chemotherapy or an antibody-drug conjugate, and your last dose was within the past 28 days.
- After those 6 cycles, your cancer has either shrunk, stayed the same, or disappeared completely (confirmed by doctors).
- You are between 18 and 70 years old and are in good general health (able to do daily activities without major limitations).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.